Cost-effectiveness of using a 20-valent pneumococcal conjugate vaccine to directly protect adults in England at elevated risk of pneumococcal disease.
Expert Rev Pharmacoecon Outcomes Res
; 22(8): 1285-1295, 2022 Dec.
Article
in En
| MEDLINE
| ID: mdl-36225103
ABSTRACT
OBJECTIVES:
Despite the current pneumococcal vaccination program in England for older adults and adults with underlying conditions, disease burden remains high. We evaluated cost-effectiveness of 20-valent pneumococcal conjugate vaccine (PCV20) compared to current pneumococcal recommendations for adults in England.METHODS:
Lifetime outcomes/costs of invasive pneumococcal disease (IPD) and community-acquired pneumonia (CAP) among adults aged 65-99 years and adults aged 18-64 years with underlying conditions in England were projected using a deterministic cohort model. Vaccination with PCV20 was compared with 23-valent pneumococcal polysaccharide vaccine (PPV23) from the National Health Service perspective.RESULTS:
PCV20 was cost saving compared with PPV23 in base case and most sensitivity analyses. In the base case, replacing PPV23 with PCV20 prevented 7,789 and 140,046 cases of IPD and hospitalized CAP, respectively, and 22,199 associated deaths, resulting in incremental gain of 91,375 quality-adjusted life-years (QALYs) and incremental savings of £160M. In probabilistic sensitivity analyses, PCV20 (vs. PPV23) was cost saving in 85% of simulations; incremental cost per QALY was below £30,000 in 99% of simulations.CONCLUSIONS:
PCV20 vaccination in adults aged 65-99 years and those aged 18-64 years with underlying comorbidities in England is expected to prevent more hospitalizations, save more lives, and yield lower overall costs than current recommendations for PPV23.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Pneumococcal Infections
/
State Medicine
Type of study:
Etiology_studies
/
Health_economic_evaluation
/
Risk_factors_studies
Aspects:
Patient_preference
Limits:
Aged
/
Humans
Country/Region as subject:
Europa
Language:
En
Journal:
Expert Rev Pharmacoecon Outcomes Res
Journal subject:
FARMACOLOGIA
Year:
2022
Document type:
Article
Affiliation country:
Reino Unido